Akari Therapeutics Plc - American Depositary Shares (AKTX)
AKTX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How AKTX actually reacts to news — the realized, point-in-time move the market made, measured across 146 labeled events over the last three years with zero look-ahead.
AKTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 112 |
| 30-min | 0.00% | 45% | 126 |
| 60-min | 0.00% | 40% | 131 |
| to close | 0.00% | 48% | 145 |
| Middle 50% of AKTX reactions | -1.85% to +2.27% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 146 |
Half of all Akari Therapeutics Plc - American Depositary Shares news events land between -1.85% and +2.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AKTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AKTX's baseline. Nothing else.
Recent AKTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner | Press release | GlobeNewswire | — | +21.26% | |
| Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering | Press release | GlobeNewswire | -3.03% | -8.03% | |
| Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers | Press release | GlobeNewswire | +3.21% | -5.46% | |
| ROTH to Host 5th Annual Healthcare Opportunities Conference on September 29 in New York City | Press release | GlobeNewswire | — | +7.14% | |
| Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight | Press release | PR Newswire | -0.53% | -4.13% | |
| Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums | Press release | GlobeNewswire | +4.39% | -1.70% | |
| Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference | Press release | GlobeNewswire | -0.83% | -6.15% | |
| JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs | Press release | ACCESS Newswire | -0.83% | -6.15% | |
| Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy | Press release | GlobeNewswire | +6.16% | +8.21% | |
| Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform | Press release | GlobeNewswire | +0.00% | +7.56% | |
| Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation | Press release | GlobeNewswire | — | +6.13% | |
| Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity | Press release | GlobeNewswire | +2.54% | +8.28% | |
| Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | Press release | GlobeNewswire | -0.44% | -17.38% | |
| Complement 3 Glomerulopathy Market Set for Transformation: 4 Emerging Therapies Leading the Next Growth Phase | DelveInsight | Press release | PR Newswire | — | -5.00% | |
| Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board | Press release | GlobeNewswire | +0.00% | +42.15% | |
| Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones | Press release | GlobeNewswire | -1.38% | -4.44% | |
| Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026 | Press release | GlobeNewswire | +4.79% | +9.92% | |
| Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance | Press release | GlobeNewswire | +0.51% | +39.38% | |
| Akari Therapeutics Announces $5.5 Million Private Placement Offering | Press release | GlobeNewswire | +6.35% | +63.17% | |
| Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models | Press release | GlobeNewswire | +0.30% | +84.17% | |
| Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | Press release | GlobeNewswire | — | +0.00% | |
| Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets | Press release | GlobeNewswire | -4.58% | -41.60% | |
| Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload | Press release | GlobeNewswire | +0.00% | +1.08% | |
| Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors | Press release | GlobeNewswire | +2.59% | -2.00% | |
| Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing | Press release | GlobeNewswire | +7.81% | +29.98% | |
| Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC | Press release | GlobeNewswire | -1.61% | +2.35% | |
| Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing | Press release | GlobeNewswire | -3.51% | -11.28% | |
| Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 | Press release | GlobeNewswire | -8.25% | -18.21% | |
| Akari Therapeutics Announces ADS Ratio Change | Press release | GlobeNewswire | -8.25% | -18.21% | |
| Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala | Press release | GlobeNewswire | +0.34% | -13.21% | |
| Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board | Press release | GlobeNewswire | -2.20% | -1.82% | |
| Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board | Press release | GlobeNewswire | +0.08% | -2.64% | |
| Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference | Press release | GlobeNewswire | -2.79% | -2.83% | |
| Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline | Press release | GlobeNewswire | +2.01% | -1.36% | |
| Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | Press release | GlobeNewswire | +4.66% | +1.35% | |
| Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors | Press release | GlobeNewswire | -0.61% | -2.09% | |
| Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 | Press release | GlobeNewswire | +5.63% | -0.11% | |
| Akari Therapeutics to Present at the 2026 Biotech Showcase | Press release | GlobeNewswire | +1.85% | +2.69% | |
| Akari Therapeutics Issues 2025 End of Year Letter to Shareholders | Press release | GlobeNewswire | -1.54% | +3.28% | |
| Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial | Press release | GlobeNewswire | +0.00% | -7.29% | |
| Akari Therapeutics Releases Virtual Investor “What This Means” Segment | Press release | GlobeNewswire | -1.11% | +0.49% | |
| Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market | Press release | GlobeNewswire | -26.47% | -25.41% | |
| Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer | Press release | GlobeNewswire | -8.98% | +3.39% | |
| Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment | Press release | GlobeNewswire | +1.41% | +6.25% | |
| Akari Therapeutics Announces Release of the Next CEO Corner Segment | Press release | GlobeNewswire | +3.29% | +0.41% | |
| Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer | Press release | GlobeNewswire | +0.00% | +7.32% | |
| Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors | Press release | GlobeNewswire | -3.00% | -2.03% | |
| Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available | Press release | GlobeNewswire | -3.83% | +5.14% | |
| Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP | Press release | GlobeNewswire | +2.50% | -1.44% | |
| Akari Therapeutics Announces Launch of CEO Corner Platform | Press release | GlobeNewswire | -1.82% | -3.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AKTX section they belong to.
Where else AKTX is measured.
AKTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BioLineRx Ltd. - American Depositary Shares (BLRX) | 148 | -0.82% | 40% |
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Akari Therapeutics Plc - American Depositary Shares's median reaction calculated?
Every labeled AKTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 146 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of AKTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AKTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.